X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the agreement, Allogene will use Arbor’s proprietary CRISPR gene-editing technology in its next generation AlloCAR T platform, ALLO-329, for the treatment of autoimmune disease (AID).
Lead Product(s): ALLO-329
Therapeutic Area: Immunology Product Name: ALLO-329
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Allogene Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement March 12, 2024
Details:
4DMT and Arbor will co-develop and co-commercialize up to six AAV-delivered CRISPR/Cas-based therapeutic candidates for central nervous system (CNS) diseases, including amyotrophic lateral sclerosis (ALS).
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Recipient: 4D Molecular Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership January 03, 2024
Details:
Under the terms of the agreement, Vertex Pharmaceuticals incorporated will receive rights to Arbor’s novel precision editing technology for up to three diseases.
Lead Product(s): Undisclosed
Therapeutic Area: Endocrinology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Vertex Pharmaceuticals
Deal Size: $1,200.0 million Upfront Cash: Undisclosed
Deal Type: Expanded Collaboration January 11, 2023
Details:
As part of the agreement, the companies will combine the optimized delivery of Acuitas' highly validated LNP technology with Arbor’s differentiated, proprietary CRISPR gene editing technology designed for use in vivo in patients with rare liver diseases.
Lead Product(s): LNP-based Gene Therapy
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Acuitas
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement August 25, 2022
Details:
The collaboration leverages Arbor’s proprietary CRISPR gene-editing technology and TCR 2’s’ TRuC platform, which has demonstrated clinical activity in multiple treatment-refractory mesothelin-expressing solid tumor indications with its lead autologous program Gavo-cel.
Lead Product(s): Gavocabtagene autoleucel,Fludarabine Phosphate,Cyclophosphamide
Therapeutic Area: Oncology Product Name: Gavo-cel
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: TCR2 Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 04, 2022
Details:
Arbor plans to use the proceeds to advance its lead programs in liver and CNS disease into the clinic and progress a pipeline of precision editing therapeutics, while continuing to invest in its novel discovery engine to develop the next generation of gene editing technology.
Lead Product(s): Nuclease Therapies
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Partner/Sponsor/Collaborator: Temasek Life Sciences Laboratory
Deal Size: $215.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing November 09, 2021
Details:
Under this new partnership, Vertex will receive rights to use Arbor’s technology to research and develop ex vivo engineered cell therapies towards Vertex’s goal of generating fully differentiated, insulin-producing hypoimmune islet cells for the treatment of type 1 diabetes.
Lead Product(s): Ex-vivo Engineered Cell Therapies
Therapeutic Area: Endocrinology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Vertex Pharmaceuticals
Deal Size: $1,200.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration August 24, 2021
Details:
The agreement aims to utilize Arbor’s gene editing technologies to engineer hematopoietic stem cells, towards the goal of developing therapies for the treatment of blood cancers, such as acute myeloid leukemia.
Lead Product(s): Engineered hematopoietic stem cell
Therapeutic Area: Oncology Product Name: VOR33
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Vor Biopharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration September 29, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
